Autologous Transplants for Multiple Myeloma: Updates from the 2008 American Society of Hematology Meeting

An Update of Treatments for Multiple Myeloma: Results from the 2006 American Society of Hematology Meeting

What is New in Multiple Myeloma? - Update From ASH 2005

New Velcade®-melphalan Transplant Regimen for Multiple Myeloma (11/20/2009)
Researchers from France have reported encouraging results with adding Velcade® (bortezomib) to high-dose melphalan followed by autologus stem cell infusion for initial treatment of patients with newly diagnosed multiple myeloma. The details of this Phase II study appeared in an early online publication in Blood on November 2, 2009.

Addition of Thalomid® to Autologous Stem Cell Transplantation May Improve Outcomes in Patients with Myeloma (10/23/2009)
Researchers from Italy have reported that “the addition of first-line thalidomide to double ASCT [autologous stem cell transplant] improved clinical outcomes” for patients with multiple myeloma. The details of this study appeared in the October 20, 2009 issue of the Journal of Clinical Oncology.

New Proteasome Inhibitor, Carfilzomab, Has Significant Activity in Relapsed Myeloma (10/6/2009)
Researchers affiliated with the Multiple Myeloma Research Consortium (MMRC) have reported that carfilzomab monotherapy is highly active in patients with relapsed myeloma and can be administered safely for at least one year in responding patients. The details of this study were presented at the Joint ECCO 15-34^th ESMO Multidisciplinary Congress in Berlin, September 20-24, 2009.

Pomalidomide Active for Treatment of Anemia of Myelofibrosis (8/21/2009)
Researchers involved in an international trial have reported that pomalidomide is active for the treatment of anemia associated with myelofibrosis. The details of this study appeared in an early online publication in the Journal of Clinical Oncology on August 3, 2009.

Pesticides Linked to Monoclonal Gammopathy of Undetermined Significance (MGUS) (7/1/2009)
Researchers from the National Cancer Institute have reported that individuals who apply pesticides to crops are twice as likely as the general population to develop monoclonal gammopathy of undetermined significance (MGUS), which can lead to multiple myeloma. The details of this study appeared in the June 18, 2009 issue of Blood.